Amgen and Pfizer's PCSK9 inhibitors step hopefully 'down the line'
This article was originally published in Scrip
Executive Summary
Further Phase II data supporting a strong efficacy profile for Amgen’s and Pfizer’s PCSK9 inhibitors –AMG 145 and RN316 (PF-04950615) – generated excitement at the American Heart Association meeting in Los Angeles as they make a compelling clinical case for the drugs’ additive effect to statins, raising the hope that in future most patients will be able to reach their LDL-cholesterol goals with this new drug class.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.